Pharm-Olam is a midsized CRO committed to ease of collaboration and delivery. We deliver agile, innovative and flexible full-service solutions designed to support and partner with small to mid-size biotech companies through Phase I-IV clinical research. We specialize in the development of biologics and vaccines for the prevention, treatment and curing of oncology-hematology, rare diseases, allergies, autoimmune disorders, and infectious diseases. As a global CRO, Pharm-Olam understands the unique challenges presented in these areas.
We also provide federal research solutions and have collaborated on over $778 million in government contracts, spanning several agencies, including CDC, DOD, and NIH. Pharm-Olam is also a member of the Medical CBRN Defense Consortium (MCDC) and in October 2020 was selected by BARDA to support Medical Countermeasure (MCM) development in a 5 year contract worth $250 million. Whether you have already secured federal funding or are still wondering what options you have, Pharm-Olam has the experience to lead you through the nuances and requirements of government-funded research.